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Herpes simplex virus type 1 (HSV-1) infection of the corneal stroma remains a major cause of blindness.
Primary cultures of corneal fibroblasts (CF) were tested and found susceptible to HSV-1 entry, which was
confirmed by deconvolution imaging of infected cells. Plaque assay and real-time PCR demonstrated viral
replication and hence a productive infection of CF by HSV-1. A role for glycoprotein D (gD) receptors in
cultured CF was determined by gD interference assay. Reverse transcription-PCR analysis indicated expres-
sion of herpesvirus entry mediator and 3-O-sulfated (3-OS) heparan sulfate (HS)-generating enzyme 3-O
sulfotransferase 3 (3-OST-3) but not nectin-1 or nectin-2. Subsequently, HS isolated from these cells was found
to contain two distinct disaccharides (IdoUA2S-AnMan3S and IdoUA2S-AnMan3S6S) that are representative
of 3-OST-3 activity. The following lines of evidence supported the important role of 3-OS HS as the mediator
of HSV-1 entry into CF. (i) Blockage of entry was observed in CF treated with heparinases. The same enzymes
had significantly less effect on HeLa cells that use nectin-1 as the entry receptor. (ii) Enzymatic removal of cell
surface HS also removed the major gD-binding receptor, as evident from the reduced binding of gD to cells.
(iii) Spinoculation assay demonstrated that entry blockage by heparinase treatment included the membrane
fusion step. (iv) HSV-1 glycoprotein-induced cell-to-cell fusion was inhibited by either prior treatment of cells
with heparinases or by HS preparations enriched in 3-OS HS. Taken together, the data in this report provide
novel information on the role of 3-OS HS in mediating infection of CF, a natural target cell type.
Herpes simplex virus type 1 (HSV-1) infection is the most
common cause of infectious blindness in developed countries
(33, 34, 49, 62). Following initial infection of epithelial cells,
HSV establishes latency in the sensory nerve ganglia of the
host (26, 58). The virus emerges sporadically from latency and
causes lesions on mucosal epithelium, skin, and the cornea.
Prolonged or multiple recurrent episodes of corneal infections
can result in vision impairment or blindness due to the devel-
opment of herpetic stromal keratitis (HSK) (8, 23, 28, 42, 44,
71). The HSK condition is typically characterized by inflam-
mation leading to scarring, thinning, and vascularization of the
corneal stroma (12, 15, 19, 24, 33, 34). It accounts for 20 to
48% of all recurrent ocular HSV infection cases (33).
Primary infection begins with the entry of HSV into host
cells. It is a complex process initiated by specific interaction of
viral envelope glycoproteins and host cell surface receptors
(10, 18, 52, 58–60). Both HSV-1 and HSV-2 use glycoproteins
B and C (gB and gC, respectively) to mediate their initial
attachment to cell surface heparan sulfate (HS) proteoglycans
(25, 53, 67). Binding of herpesviruses to HS proteoglycans
likely precedes a conformational change that brings viral gD to
the binding domain of host cell surface gD receptors (29–31).
Thereafter, a concerted action involving gD, its receptor, three
additional HSV glycoproteins (gB, gH, and gL), and possibly
an additional gH coreceptor triggers fusion of the viral enve-
lope with the plasma membrane of host cells (43, 45, 50).
Subsequently, viral capsids and tegument proteins are released
into the cytoplasm of the host cell.
The gD receptors include cell surface molecules derived
from three structurally unrelated families. These include a
member of the tumor necrosis factor receptor family (40), two
members of the nectin family of receptors (21), and the prod-
uct of certain 3-O-sulfated (3-OS) sulfotransferases (3-OSTs),
3-OS HS (41, 55, 57–60). Herpesvirus entry mediator (HVEM
or TNFRSF14) principally mediates entry of HSV-1 and
HSV-2 (40, 66) into human T lymphocytes and trabecular
meshwork cells and is expressed in many fetal and adult human
tissues, including the lung, liver, kidney, and lymphoid tissues
(27, 32, 37, 40, 62). Nectin-1 and nectin-2, also known as
herpesvirus entry proteins C B, respectively, belong to the
immunoglobulin superfamily (7, 13, 21). Both nectin-1 and
nectin-2 mediate entry of HSV-1 and HSV-2, but only nectin-1
mediates bovine herpesvirus type 1 entry (9, 21, 36, 38, 39, 65).
The HSV-1 entry-mediating activity of nectin-2 is limited to
some mutant strains only (65). Nectin-1 is extensively ex-
pressed in human cells of epithelial and neuronal origin (22,
48, 56, 58), while nectin-2 is widely expressed in many human
tissues, but with only limited expression in neuronal cells and
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keratinocytes (5). The nonprotein receptor 3-OS HS is ex-
pressed in multiple human cell lines (e.g., neuronal and endo-
thelial cells) and mediates entry of HSV-1 but not HSV-2 (16,
17, 55, 59, 60).
Although the corneal stroma is a potential target of HSV-1
infection, the role of HSV-1 gD receptors in viral entry into the
cells of the stroma remains poorly understood (1, 3). It has
been proposed that HSV-1 travels from the corneal epithelium
to sensory ganglia and then returns to the stroma to cause
disease (47). To study HSV entry and the role of the entry
receptor(s), we used in vitro primary cultures of corneal fibro-
blasts (CF) derived from human corneal stroma. We hypoth-
esized that one or more of the known entry receptors would
mediate entry of HSV-1 into CF. Our objectives were (i) to
investigate the susceptibility of cultured human CF to produc-
tive HSV-1 entry and replication, (ii) to determine the expres-
sion of HSV-1 gD receptors in cultured CF, and (iii) to identify
a gD receptor(s) crucial for HSV-1 entry into cultured CF.
This study, the first of its kind, demonstrated a significant role
for, and the physiological significance of, modified HS (3-OS
HS) as a receptor for HSV-1 entry into a natural-target human
cell type.
MATERIALS AND METHODS
Cells, viruses, and antibodies. P. G. Spear (Northwestern University) provided
wild-type Chinese hamster ovary (CHO-K1) cells, viruses, and the anti-Myc,
anti-HVEM (40) antibodies used throughout this study. Recombinant cytomeg-
alovirus (CMV; Towne strain RC256) was obtained from the American Type
Culture Collection. Wild-type CHO-K1 cells and African green monkey kidney
(Vero) cells were grown as previously described (40). CHO-K1 cells stably
expressing HVEM plasmid pBec10 (40) and plasmid 3-OST-3 (68) were grown in
Ham’s F12 medium (Invitrogen) under G418 sulfate (400 g/l; Cellgro) selec-
tion. Human lung fibroblasts (LF) provided by Steven J. Ackerman (University
of Illinois at Chicago) were grown in Dulbecco’s modified Eagle medium
(DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS). Cul-
tures of human CF were derived from the corneas of donors 24, 38, 47, 49, and
51 years of age obtained from the Illinois Eye Bank, Chicago, IL. The procure-
ment of tissues was in accordance with the Declaration of Helsinki. As previously
described (70), CF were grown in L-glutamine-containing DMEM (Invitrogen)
supplemented with 15% FBS. Cells were trypsinized and passaged after reaching
confluence. CF from the third to the sixth passages used in this study showed
nearly identical results in HSV-1 entry, replication, receptor expression, and anti-
body-blocking assays. Recombinant -galactosidase-expressing HSV-1(KOS)
tk12 (65) and HSV-1(KOS) gL86 (40) were used. Green fluorescent protein
(GFP)-expressing HSV-1(K26GFP) (11) was provided by P. Desai (Johns Hop-
kins University, Baltimore, MD). The viral stocks were propagated at a low
multiplicity of infection (MOI) in complementing cell lines, their titers were
determined on Vero cells, and they were stored at 80°C.
Viral entry assays. Viral entry assays were based on quantitation of -galac-
tosidase expressed from the viral genome or by CHO-IE8 cells, in which
-galactosidase expression is inducible by HSV infection (40). Cells (CF, LF,
wild-type CHO-K1 cells, and CHO-K1 cells stably expressing HVEM and
3-OST-3) were plated at 2  10 4 per well in 96-well plates at least 16 h prior to
infection. HSV entry into CF was determined by o-nitrophenyl--D-galacto-
pyranoside (ONPG) assay and also by 5-bromo-4-chloro-3-indolyl--D-galacto-
pyranoside (X-Gal) as previously described (40). Microscopy was performed with
the 20 objective of an inverted microscope (Axiovert 100 M; Zeiss). All exper-
iments were repeated a minimum of three times unless otherwise noted.
Deconvolution microscopy. Confluent monolayers of cultured CF (0.5  106)
on cover glass (20 by 20 mm; Fisher Scientific, Pittsburgh, PA) were infected at
37°C with GFP-tagged HSV-1(K26GFP) (11) at 50 PFU/cell. After 90 min, cells
were washed in phosphate-buffered saline (PBS) and mounted upside down on
the microscope slides in Vectashield mounting medium (Vector Laboratories,
Inc., Burlingame, CA). Stack microscopy was carried out with Metamorph im-
aging software and a Zeiss Axiovert 100 M system equipped with 63, 1.4
numerical aperture oil immersion objectives. The images were deconvolved with
Auto Deblur software (AutoQuant Imaging, Inc.). Orthogonal sections were
made in a z stack of 25 images (0.4-m interval). A histogram of an individual
stack taken as a part of z series was plotted for maximum light intensity. The
picture was produced in Adobe Photoshop 7.0.
Plaque assay. Virus replication was examined by plaque assay. A monolayer of
cultured CF (approximately 4  106 cells per 25-ml flask) was infected (MOI,
0.01) with HSV-1(KOS) or mock infected with PBS alone for 2 h at 37°C.
Wild-type CHO-K1 cells and CHO-K1 cells expressing 3-OST-3-modified 3-OS
HS infected under similar conditions were used as negative and positive controls,
respectively. After removal of the inoculum, monolayers were overlaid with
DMEM containing 2.5% heat-inactivated calf serum and incubated at 37°C until
the time of harvest (12 to 48 h). Infectious virus titers were determined on Vero
cells cultured in triplicate by using an overlay of medium containing methylcel-
lulose. In order to block secondary plaque formation, human immunoglobulin G
(IgG; Sigma) was added to the inoculum. The cells were washed with PBS buffer,
fixed in alcohol, and stained with Giemsa stain. Infectivity was recorded as the
number of PFU.
HSV-1 gD interference assay. CF were transfected with TransIT-TKO reagent
(Mirus Corporation) with an HSV-1 gD expression plasmid (pPEP99) (20) or a
control plasmid (pCDNA3) in six-well dishes (1.0 g of plasmid DNA total per
well). The interference assay was performed as described elsewhere (20).
Detection of gD receptors by reverse transcription (RT)-PCR analysis. Total
RNA was isolated from cultured human CF and HeLa cells with a QIAGEN
RNeasy kit (QIAGEN Corp., Valencia, CA). SUPERSCRIPT II reverse trans-
criptase (Invitrogen Corp.) was used for RT. PCR amplification of cDNAs was
done with primers 5-TCTCTGCTGCCAGACA-3 and 5-GCCACAGCAGA
ACAGA-3 for HVEM, primers 5-TCCTTCACCGATGGCACTATCC-3 and
5-TCAACACCAGCAGGATGCTC-3 for nectin-1, and primers 5-AGAAGC
AGCAGCACCAGCAG-3 and 5-GTCACGTTCAGCCAGGA-3 for nectin-2.
The 3-OST-3 sequences were amplified with primers 5-CAGGCCATCATCAT
CGG-3 and 5-CCGGTCATCTGGTAGAA-3. RT-PCR analysis was per-
formed as described previously (54). The expected sizes of the PCR products
were 1,270 bp for HVEM, 738 bp for nectin-1, 616 bp for nectin-2, and 736 bp
for 3-OST-3.
Determination of the presence of 3-OS HS in cultured CF. (i) Metabolic
labeling and preparation of 35S-HS. CF were grown to 90% confluence in T-25
flasks. After removal of growth medium, cells were incubated with 5 ml labeling
medium (F-12 medium, 10% dialyzed FBS, 1 mCi/ml Na235SO4) for 10 h at 37°C.
One milliliter of 1 mg/ml pronase (Sigma) in a buffer containing 240 mM sodium
acetate (NaAcO, pH 6.5) and 1.92 M NaCl was then added to lyse the cells. After
incubation at 37°C overnight, the resultant samples were subjected to DEAE-
Sephacel column chromatography. The column was washed with 10 ml buffer A
(20 mM NaAcO [pH 5], 150 mM NaCl) and eluted with 5 ml buffer B (20 mM
NaAcO [pH 5], 1 M NaCl). The eluent was dialyzed against 50 mM ammonium
bicarbonate with a membrane with a molecular weight cutoff of 14,000 and dried.
The samples were reconstituted in H2O and subjected to  elimination under
alkaline conditions at 46°C for 16 h. The samples were then subjected to phenol-
chloroform extraction to remove proteins. 35S-HS was precipitated by 75%
ethanol. Chondroitin sulfate was removed by incubation with chondroitinase
ABC (Sigma) at 37°C for 3 h.
(ii) Disaccharide analysis of 35S-HS. The 35S-HS isolated from CF and
CHO-K1 cells was degraded with nitrous acid at pH 1.5, followed by reduction
with sodium borohydride (35). The resultant 35S-labeled disaccharides were
desalted on a Bio-Gel P-2 column (0.75 by 200 cm) that was equilibrated with 0.1
M ammonium bicarbonate at a flow rate of 4 ml/h. The disaccharides were
resolved with a C18-reversed phase column (0.46 by 25 cm; Vydac) under reverse-
phase ion-pairing high-performance liquid chromatography (RPIP-HPLC) con-
ditions. Briefly, the column was eluted with acetonitrile at 8% for 30 min,
followed by 15% for 15 min and then by 19.5%, in a solution containing 38 mM
ammonium phosphate monobasic, 2 mM phosphoric acid, and 1 mM tetra-
butylammonium phosphate monobasic (Fluka) at a flow rate of 0.5 ml/min. The
identities of the disaccharides were determined by coelution with appropriate
3H-labeled and 35S-labeled disaccharides (35, 57).
Binding of 3-OS HS derived from cultured CF to HSV-1 gD. To assay for the
binding of 3-OS HS to gD, immunoprecipitation was carried out with anti-gD
monoclonal antibody (57). Enzyme-modified HS (100,000 to 200,000 cpm) was
incubated in a buffer containing 50 mM Tris-HCl, 150 mM NaCl, and 0.01%
Triton (pH 7) (binding buffer) and 2 mg/ml gD at room temperature for 30 min.
Anti-gD monoclonal antibody DL6 was added, and the mixture was incubated at
4°C for 1 h, followed by addition of protein A-agarose gel (80 l of a 1:1 slurry),
and agitated at 4°C for an additional hour. The HS was eluted from the gel with
1 ml of 1 M NaCl in the binding buffer.
Virus-free cell-to-cell fusion assay. In this experiment, the CHO-K1 cells
designated effector cells were cotransfected with plasmids expressing four HSV-
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1(KOS) glycoproteins, pPEP98 (gB), pPEP99 (gD), pPEP100 (gH), and
pPEP101 (gL), along with plasmid pT7EMCLuc, which expresses the firefly
luciferase gene under the control of the T7 promoter (61). In a parallel exper-
iment, human herpesvirus 8 (HHV-8) glycoproteins gB, gH, and gL (46) were
used as controls. Wild-type CHO-K1 cells express cell surface HS but lack
functional gD receptors, including 3-OS HS (60). As a result, they are resistant
to both HSV entry and virus-induced cell fusion (40, 53, 57). Cultured CF
considered target cells were cotransfected with pCAGT7, which expresses T7
RNA polymerase with the chicken actin promoter and the CMV enhancer (46).
Effector cells expressing pT7EMCLuc and pCDNA3 (devoid of any glycopro-
teins) and target CF transfected with T7 RNA polymerase alone were used as
negative controls. Activation of the reporter luciferase gene, as a measurement
of cell fusion, was examined by reporter lysis assay (Promega) at 24 h postmixing
as previously described (61).
Heparinase treatment. CF and CHO-K1 cells transfected with plasmid
3-OST-5 plated on 96-well plates were washed with Mg2- and Ca2-free PBS
and incubated at room temperature for 90 min with several dilutions of hepari-
nases II and III (4 U/ml; Sigma) or PBS alone and incubated at room temper-
ature. The cells were then washed with PBS and used for viral entry, cell-to-cell
fusion, and gD-Fc binding assays.
gD-Fc binding assay. Cultured CF and HeLa cells were plated overnight into
96-well dishes (approximately 4  104 cells/well). They were treated with hepa-
rinases II and III or with PBS buffer as described above for 2 h. This was followed
by incubation with gD-Fc (1 g/ml) for 1 h and fixation at room temperature with
2% formaldehyde and 0.02% glutaraldehyde for 15 min. The cells were washed
with PBS containing 3% BSA (Sigma) and then incubated at room temperature
sequentially with a biotinylated secondary antibody against rabbit IgG (Sigma) at
a 1:500 dilution in PBS–3% BSA for 45 min and AMDEX streptavidin-conju-
gated horseradish peroxidase (Amersham) at a 1:20,000 dilution for 30 min.
Following washing in PBS, the cells were incubated with 50 l 3,3,5,5-tetra-
methylbenzidine (Sigma) in 50 mM phosphate-citrate buffer. Products were
quantitated by use of a spectra MAX 190 enzyme-linked immunosorbent assay
reader to measure optical density at 650 nm (OD650).
Surface immunofluorescence assay. To detect the binding of gD-Fc to the
surface of CF and HeLa cells, cultured monolayers of cells (approximately 106)
were grown overnight on glass bottom culture dishes (Mat Tek Corp.). The cells
were then treated with heparinases II and III (at 4 U/ml) or with PBS, exposed
to gD-Fc for 1 h, and fixed with acetone. They were then treated with fluorescein
isothiocyanate (FITC)-conjugated anti-rabbit IgG (Sigma) and mounted on glass
slides before examination under a confocal microscope.
Spinoculation assay. Subconfluent CHO-K1 cells were transfected with 1.0 g
of DNA of HVEM (pBEC10) (40), 3-OST-5 (68), or nectin-1 (pBG38) (21).
Transfected CHO-K1 cells and cultured CF along with Vero cells were plated on
96-well dishes (approximately 104 cells/well) and allowed to grow for an addi-
tional 16 h at 37°C and 5% CO2. The cells were treated at room temperature with
heparinases II and III (4 U/ml) or PBS before spinoculation (51). Briefly, a dose
of HSV-1(KOS) gL86 and or CMV (35 PFU/cell) was added to the cells for 2 h
of incubation and the plates were transferred to 37°C. One set of heparinase-
treated cells was spun at 1,200  g at 37°C, and another set was kept at 37°C for
2 h in an incubator as previously described (51). The plates were then washed
with PBS to remove exogenous virus and incubated at 37°C for 4 h. They were
further washed with PBS, 50 l ONPG reagent was added to each well, and viral
entry was measured as described above.
RESULTS
CF are susceptible to HSV-1 entry. To determine HSV-1
entry, confluent monolayers of cultured CF were infected with
serial dilutions of recombinant HSV-1(KOS) tk12 (65),
which expresses -galactosidase upon entry into cells.
CHO-K1 cells that are naturally resistant to HSV-1 entry
were used as a negative control. Entry of HSV-1 was mea-
sured after 6 h of viral infection (60). As shown in Fig. 1A,
compared to CHO-K1 cells, HSV-1 entered CF in a dose-
dependent manner while none entered CHO-K1 cells. In com-
parison assays, human CF showed an HSV-1 dose response
similar to those of human LF cells and gD receptor (HVEM
or 3-OS HS)-containing CHO-K1 cells. By contrast, CHO-K1
cells without any receptor remained resistant to HSV-1 entry.
A representative entry result obtained with a single virus dose
of 5 PFU/cell is shown in Fig. 1B.
Visualization of GFP-tagged HSV-1 internalization in cul-
tured CF by deconvolution microscopy. GFP-tagged HSV-
1(K26GFP) (11) was used to infect cultured CF, and high-
resolution deconvolution microscopy was employed to
visualize fluorescent virus particles inside infected CF. As
shown in Fig. 1C, a majority of the cultured CF were in-
fected with fluorescent HSV-1 virions. Next, to localize the
virions inside an infected cell, the cells were stained with
4,6-diamidino-2-phenylindole (DAPI) and examined un-
der two separate channels (FITC and DAPI). The punctate
green fluorescence of virions was observed surrounding the
DAPI-stained blue nucleus. To analyze this further, decon-
volution microscopy was used. Optical sections (0.2 m thick)
were collected, and the stacks were deconvolved and analyzed
by Metamorph software. The orthogonal section of decon-
volved images sliced at two selected planes (Fig. 1D, XZ and
YZ) showed the distribution of punctate green fluorescence or
virus particles in planes surrounding the nucleus. The subse-
quent three-dimensional views, which cover the entire depth of a
cell with detailed visualization of the GFP-labeled capsid at dif-
ferent angles within the cell, further demonstrate the presence of
the virus surrounding the nucleus (transverse view in Fig. 1E and
longitudinal views in Fig. 1F to G). Analysis of individual optical
sections (z stacks) revealed that maximum florescence was re-
corded for the midsections, indicating that a majority of the viri-
ons were located in the middle (cytoplasmic) portion of the cell.
A histogram of this result is shown in Fig. 1H.
HSV-1 replicates in cultured CF. Because HSV-1 was able
to enter cultured CF, we next evaluated if entry of HSV-1 into
cultured CF led to productive replication of the virus. The
infectious yields of virus were determined by plaque assays
with Vero cells. As shown in Fig. 2A, cultured CF exposed to
HSV-1(KOS) and CHO-K1 cells expressing 3-OS HS modified
by 3-OST-3 at an MOI of 0.01 produced a larger number of
plaques over time. In contrast, CHO-K1 cells infected with
identical doses of the same virus failed to produce infectious
virions. These results, together with those of the entry assay,
show that entry of HSV-1 into cultured CF leads to productive
infection.
Expression of HSV-1 gD in cultured CF renders resistance
to HSV-1 entry. In order to determine if the gD receptors play
a role in human CF infection by HSV-1, a gD-mediated inter-
ference assay was used (20). This assay is based on the prin-
ciple that cells that are normally susceptible to viral entry
become resistant upon expression of viral gD because of
sequestration of gD receptors by cell-expressed gD (20). To
carry out the assay, human CF were transiently transfected
with an HSV-1 gD-expressing plasmid (or an equal amount
of the empty vector, pCDNA3, as a control), followed by
infection with serial dilutions of -galactosidase-expressing
HSV-1(KOS) gL86. We used recombinant human CMV as a
control that enters independently of gD receptors into cells.
As shown in Fig. 2B, HSV-1 entry into gD-expressing CF
was approximately 2.0-fold lower compared to the pCDNA3
control. Meanwhile, the expression of gD in cultured CF did
not affect CMV entry. Thus, entry into CF is likely mediated
by gD receptors expressed on the CF surface in a gD-
dependent manner. The transfection efficiency in CF was
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tested with a nectin-1–GFP-expressing plasmid. We esti-
mated that approximately 80% of cultured CF turned green
as a result of transfection under fluorescence microscopy
(data not shown).
Identification of gD receptors expressed in cultured CF.
RT-PCR analysis was performed to determine the identity of
gD receptors potentially expressed in CF. Specific primers for
HVEM, nectin-1, nectin-2, and 3-OST-3 were used. As shown
in Fig. 3A, products of the expected sizes for cDNAs encoding
HVEM and 3-OST-3, but not nectin-1 and nectin-2, were de-
tected. The cDNA obtained from HeLa cells was used as a
positive control. The absence of a nectin-1-specific product was
FIG. 1. Entry of HSV-1 into cultured CF. (A) Dose-response analysis of HSV-1 entry into CF. Cultured CF (F), along with wild-type CHO-K1
cells (■ ), were plated in 96-well plates and inoculated with twofold serial dilutions of -galactosidase-expressing recombinant HSV-1(KOS) tk12
ranging from 1 to 180 PFU/cell. After 6 h, the cells were permeabilized and incubated with ONPG substrate for quantitation of -galactosidase
activity expressed from the input viral genome. Enzymatic activity was measured by determining OD410. Data represent the mean  the standard
deviation of results in triplicate wells in a representative experiment. The experiment was repeated three times with similar results. (B) Entry of
HSV-1 into cultured CF, human LF cells, and CHO-K1 cells expressing either HVEM or 3-OS HS as a gD receptor. The cells were plated in 96-well
dishes and then treated with serial dilutions of -galactosidase-expressing recombinant HSV-1(KOS) tk12 as described for panel A. The values
shown represent the amount of reaction product detected spectrophotometrically at a single input dose of 5 PFU/cell. Data represent the mean 
the standard deviation of results in triplicate wells in a representative experiment. The experiment was repeated three times with similar results.
(C) Dark-field image of cultured CF infected with GFP-tagged HSV-1. (D) A section of the deconvolved stack showing GFP-tagged capsids near
or at the periphery of DAPI-stained blue nuclei. The vertical line to the right indicates the YZ plane of z sections. The horizontal line at the bottom
indicates the XZ plane of z sections. Images were collected on a Zeiss Axiovert 100 M microscope equipped with a 63 objective. (E) Three-
dimensional rendering of the entire deconvolved stacks. (F) Optical plane of sections presented at 90°. (G) Optical plane of sections presented at
110°. (H) Plot of maximum light intensity due to GFP-tagged HSV-1 observed per stack going from the top to the bottom of a cell.
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unexpected since it is generally thought to be well expressed in
human tissues and cell lines (21).
Demonstration of 3-OS HS on cultured CF and its ability to
bind to HSV-1 gD. Since RT-PCR analysis showed that 3-OS
HS-producing enzyme 3-OST-3 is expressed in cultured CF, we
decided to verify the presence of its product, 3-OS HS, in CF.
A disaccharide analysis of the total HS isolated from the sur-
face of CF grown in medium containing 35S-labeled sodium
sulfate was performed. The resultant 35S-labeled disaccharides
were resolved by RPIP-HPLC, and the chromatograms are
shown in Fig. 3B. By comparing the profiles of the degraded
35S-HS between wild-type CHO-K1 cells and cultured CF, we
found two unique 35S-labeled disaccharides in cultured CF.
By coelution with the appropriate disaccharide standards on
RPIP-HPLC, we identified the two 35S-lableled disaccharides to
be 3-O-sulfated disaccharides with the structures of IdoUA2S-
AnMan3S (eluted at 32 min) and IdoUA2S-AnMan3S6S (eluted
at 65 min). Of note is that IdoUA2S-AnMan3S are the represen-
tative disaccharides of 3-OST-3-modified HS believed to be parts
of the gD-binding site in 3-OST-3-modified HS that contribute to
the activity in assisting HSV-1 entry (57).
Next, we examined the isolated HS for its gD-binding ability
(57). The binding of HS and gD was determined by incubating
modified 35S-HS with gD, followed by immunoprecipitation
with anti-gD monoclonal antibody DL6 to precipitate the com-
plex of 35S-HS and gD. When CHO-K1 cells were the source of
HS, binding to gD was 5.3%  0.6%, and when the HS source
was CF, binding to gD was 9.8%  0.4%. These results showed
that HS isolated from cultured CF exhibited about a twofold
increase in gD binding compared to the control HS isolated
from CHO-K1 cells, which naturally lack 3-OS HS (14). A
similar increase in gD binding was reported for 3-OS HS mod-
ified in vitro by 3-OST-3 (57). Taken together, these results
suggest that cultured CF expresses 3-OST-3-modified HS di-
saccharides capable of HSV-1 gD binding.
Determination of the significance of HS as the mediator of
entry and gD binding to cultured CF. Expression of 3-OS HS
raised the possibility that it could be a mediator of HSV-1 entry
into CF. Since cells that use 3-OS HS as the major entry receptor
become significantly more resistant to HSV-1 upon removal of
HS from the surface (57), we decided to compare heparinase-
treated CF with HeLa cells, which use nectin-1 as the major
mediator of entry (7). As an additional control, we also tested
3-OST-5-expressing CHO-K1 cells in a parallel assay. As shown
in Fig. 4A, heparinase-treated CF and 3-OST-5-expressing
CHO-K1 cells were resistant to HSV-1 entry compared to the
untreated cells and this effect was considerably less pronounced
(only about 25% reduction) in identically treated HeLa cells.
Moderate resistance was expected since HS plays a role in virus
attachment, and this observation is similar to what has been
shown before (57). Next, we tested by cell enzyme-linked immu-
nosorbent assay if a soluble recombinant form of HSV-1 gD or
gD-Fc (20, 41, 57, 63) would bind cultured CF and whether this
binding could be adversely affected by removal of HS from the
surface (41, 57, 63). Cells either treated with heparinases or mock
treated were allowed to bind equal amount of gD, and binding
was detected with a spectrophotometer. Figure 4B shows that gD
binding to HeLa cells was not affected by heparinase treatment;
however, the binding of gD to CF was reduced by about 75%.
This finding strongly suggests that gD-binding receptors were
specifically removed upon heparinase treatment in CF but not in
HeLa cells. To generate further evidence for this phenomenon,
binding of gD to cells was also examined by immunofluorescence.
Once again, virtually no fluorescence (gD binding) was detected
in heparinase-treated CF and this effect was not seen in identi-
cally treated HeLa cells (Fig. 4C). This indicated that heparinase
treatment specifically removed receptors in CF but not in HeLa
cells.
Spinoculation fails to restore HSV-1 entry into heparinase-
treated cultured CF or CHO-K1 cells expressing 3-OST-5. To
verify that the significance of HS is not limited to the attachment
of virions to cultured CF, we made use of the spinoculation assay
FIG. 2. Infectious yields of HSV-1 and involvement of gD recep-
tors in viral infection. (A) HSV-1 replicates in cultured CF. Confluent
monolayers of CF (E) and wild-type CHO-K1 cells (F) and CHO-K1
cells expressing 3-OS HS modified by 3-OST-3 () were infected with
HSV-1 at 0.01 PFU per cell for 90 min at 37°C. Inoculums were
harvested at 12 to 48 h postinfection. The infectious-virus titer (PFU
per milliliter) determined in triplicate in Vero cells by plaque assay
indicates that the viral titer in cultured CF increased over time. Data
represent the mean  the standard deviation of results in triplicate
wells in a representative experiment. Experiments were repeated three
times, yielding similar results. (B) Receptors for gD are important for
infection of CF. Cultured CF were transfected with an HSV-1 gD
expression plasmid and infected either with HSV-1 (E) or with CMV
(ƒ). In parallel, CF infected with the empty vector pCDNA3 were
infected with either HSV-1 (F) or CMV (). Reporter enzyme ac-
tivity, as a measurement of viral entry, was measured with a spectro-
photometer at 410 nm.
8974 TIWARI ET AL. J. VIROL.
(51). This assay has recently been used to determine whether the
effect of enzymatic removal of HS is limited to the initial attach-
ment of the virus to cells alone or includes membrane fusion as
well (51). The spinoculation assay is based on the principle
that in cells lacking HS, the attachment but not fusion that
is mediated by gD receptors can be substituted for by spin-
ning cells and virions together at 1,200  g (51). Thus, for
each cell type (CF, Vero, nectin-1, HVEM, or 3-OST-5-express-
ing CHO-K1 cells), a set of heparinase-treated cells was spin-
oculated while another was infected with an identical viral dose
in an incubator (1  g) as a control. A third set of cells was
mock treated (with buffer alone) and infected with the same
viral dose in the incubator. As shown in Fig. 5A, in all groups
the mock-treated cells (black bars) exhibited the highest entry,
which was reduced in cells with heparinase treatment (white
bars). The most noteworthy results were seen with heparinase-
treated and spinoculated cells (gray bars). While entry was
recovered to almost the mock-treated levels in most cases, CF
and 3-OST-5-expressing CHO-K1 cells showed no recovery of
entry into those cells upon spinoculation. The lack of recovery
of entry upon spinoculation has been attributed to loss of the
gD receptor upon heparinase treatment (51). Thus, similar to
3-OST-5-expressing CHO-K1 cells, HSV-1 likely uses 3-OS-HS
for fusion of its envelope with the plasma membrane of CF
during entry. In a separate experiment, CMV was used as a
control that enters CF via gD-independent receptors. Spinocu-
lation of heparinase-treated CF restored CMV entry but not
HSV-1 entry (Fig. 5B).
FIG. 3. Expression of HVEM and 3-OST-3 mRNAs in cultured CF. (A) RT-PCR analysis of the expression of HVEM- and 3-OST-3 (as a
surrogate marker for 3-OS HS)-specific messages in CF and HeLa cells (served as a control). The cDNAs were produced from total RNA isolated
from the cells. The PCR products were separated by electrophoresis on an agarose gel and stained with ethidium bromide. Molecular size markers
are indicated on the left (sizes are in kilobases). (B) RPIP-HPLC chromatograms of the disaccharide analysis of HS isolated from CF and CHO-K1
cells. 35S-HS was extracted from CHO-K1 cells (top) and CF (bottom) after they were incubated with Na2
35SO4. Extracted HS was then
depolymerized by nitrous acid at pH 1.5, followed by sodium borohydride reduction. The resultant 35S-labeled disaccharides were resolved by
RPIP-HPLC. The elution positions of disaccharides are indicated by arrows, where arrow 1 represents IdoUA2S-AnMan3S, arrow 2 represents
IdoUA2S-AnMan6S, and arrow 3 represents IdoUA2S-AnMan3S6S.
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3-OS HS is required for HSV-1 glycoprotein-induced cell-
to-cell fusion of cultured CF. To verify that 3-OS-HS is indeed
the mediator of the membrane fusion that occurs during
HSV-1 entry into CF, we used a quantitative and efficient
cell-to-cell fusion assay (4, 61). It has been shown that, similar
to the membrane fusion that occurs during entry, cells express-
ing HSV-1 glycoproteins gB, gD, gH, and gL fuse with cells
expressing gD receptors (46), and thus cell-to-cell fusion mim-
ics the minimum requirement for entry. First, we studied the
significance of HS in the fusion of CF with glycoprotein-ex-
pressing CHO cells. HS dependence is a way to determine
whether 3-OS HS is the principal mediator of membrane fu-
sion since, unlike nectin-1 and HVEM, which do not require
HS for membrane fusion (61), 3-OS HS-mediated cell fusion is
highly dependent on the expression of HS on the cell surface
(61). As expected (Fig. 6A), fusion of 3-OST-3-expressing
CHO-K1 cells with effector cells (expressing the glycoproteins)
were significantly (about 90%) reduced upon heparinase treat-
ment, and a similar result was seen with CF but not with HeLa
cells that use nectin-1 as the gD receptor (7, 63). In a separate
set of experiments, we used cells expressing HHV-8 glycopro-
teins gB, gH, and gL to test whether the heparinase treatment
effect on CF is HSV-1 specific. In this case, heparinase treat-
ment had no effect on cell fusion (Fig. 6B).
To verify this result, a competition assay was performed with
soluble forms of HS. Approximately 1.0 g/ml soluble HS from
bovine kidney either left unmodified (UnHS) or modified in
vitro with one of the purified enzymes (3-OST-1, 3-OST-3A, or
3-OST-5) (6, 35) was added to glycoprotein-expressing effector
cells prior to mixing with cultured CF (used as target cells).
3-OST-1 is known not to generate gD receptors, while 3-OST-3
and 3-OST-5 generate gD receptors that are almost identical in
structure and are essentially interchangeable for most experi-
mental purposes (57, 61, 68). The extent of 3-O sulfation to the
HS was monitored by determining the incorporation of 35S-
sulfate into the polysaccharide after in vitro modification by
3-OSTs as previously described (57). The estimated numbers
of 3-O-sulfate groups per HS polysaccharide chain was 1.1
sulfate groups per chain for 3-OST-1-modified HS, while for
both 3-OST-3- and 3-OST-5-modified HS the value was 1.3
sulfate groups per chain. The concentration of unlabeled HS
was measured with alcian blue (2). The glycoprotein expressing
effector cells that received mock HS treatment (buffer alone)
were considered a control (untreated). As shown in Fig. 6C,
the membrane fusion was impaired when HS was 3-O sulfated
in vitro by either 3-OST-3 or 3-OST-5. In contrast, unmodified
HS (UnHS) or 3-OST-1-modified HS had no significant neg-
ative effects on the fusion. Since the cell-to-cell fusion leads to
polykaryocyte (multinucleated giant cell) formation, we also
examined the effects of soluble forms of HS in blocking this
phenomenon. The unmodified and 3-OST-1-modified forms of
FIG. 4. Effect of heparinase treatment on HSV-1 entry and gD
binding to CF. (A) Effect of heparinase treatment on HSV-1 entry.
Cultured CF, HeLa cells, or control CHO-K1 cells expressing 3-OST-5
were treated with heparinases II and III (4 U/ml) in 96-well tissue
culture dishes. A separate set of cultured cells were mock treated with
PBS alone. The cells were then exposed to HSV-1(KOS) gL86 at 35
PFU/cell, and viral entry was quantitated 6 h later, as described in the
legend to Fig. 1A. Data represent the mean  the standard deviation
of results in triplicate wells in a representative experiment. The exper-
iment was repeated three times with similar results. (B) Effect of
heparinase treatment on gD binding. Cultured CF and control HeLa
cells in 96-well dishes were treated with heparinases II and III (4 U/ml)
or incubated with buffer. The cells were then incubated with gD-Fc for
30 min, followed by fixation and incubation with a secondary antibody
and a horseradish peroxidase detection system. The values shown
(means of triplicate determinations plus standard deviations) repre-
sent the amounts of binding product detected spectrophotometrically
(OD650). (C) Confocal imaging of gD binding to heparinase-treated
cells. Cultured HeLa cells and CF were plated in glass bottom culture
dishes and grown overnight. The cells were treated with heparinases II
and III (4 U/ml) or mock treated with buffer. After incubation with
gD-Fc, the cells were washed, fixed with acetone, and incubated with
FITC-conjugated anti-rabbit IgG. Micrographs of representative HeLa
cells and CF are presented to show gD-Fc binding with or without
heparinase treatment with a Leica confocal microscope.
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HS failed to block but 3-OST-3- and 3-OST-5-modified HS
effectively blocked polykaryocyte formation (data not shown).
Taken together, our results not only demonstrate the specific-
ity of different forms of in vitro-modified soluble 3-OS HS in
FIG. 6. Role of 3-OS HS in membrane fusion. (A) Enzymatic re-
moval of cell surface HS blocks HSV-1-induced cell fusion in cultured
CF. CHO-K1 cells expressing 3-OST-3 and naturally susceptible HeLa
cells were used as controls. Target cells (CHO-K1 3-OST-3, CF, and
HeLa) were treated with heparinase (black bars) or left untreated
(white bars) prior to cocultivation with effector cells expressing four
essential HSV-1 glycoproteins (gB, gD, gH, and gL). The luminometer
readings (relative light units [RLU]) for untreated cells of each kind
were determined three or more times, and the mean value was as-
signed a value of 100%. The number of relative light units obtained for
untreated cells was then normalized accordingly to obtain the percent-
ages shown. Significant difference compared to the heparinase-un-
treated controls, P  0.01. (B) Enzymatic removal of cell surface HS
does not block HHV-8 envelope glycoprotein-induced cell-to-cell fu-
sion in CF. CHO-K1 cells, effector cells that express HHV-8 envelope
glycoproteins (gB, gH, and gL) or control plasmid pCDNA3 were
mixed at a 1:1 ratio with heparinase-treated or untreated CF. The
percentage values were calculated as described above. (C) Soluble
3-OS HS generated by 3-OST-3 and 3-OST-5 but not 3-OST-1 or
unmodified HS (UnHS) inhibits cell-to-cell fusion in cultured CF.
Effector cells were treated with 1.0 g of unmodified HS (UnHS) or
purified 3-OSTs generated by specific enzymes (3-OST-1, 3-OST-3,
and 3-OST-5) or mock treated as a positive control (white bar) prior to
being mixed with target cells. Untreated effector cells mixed with
cultured CF or 3-OST-3-expressing target cells served as a control.
Luciferase activity was measured 24 h after cocultivating the effector
and target cells. The number of relative light units shown is from one
experiment performed in triplicate.
FIG. 5. Spinoculation of heparinase-treated cells recovers entry
into Vero cells and nectin-1- or HVEM-expressing CHO-K1 cells but
not cultured CF or 3-OST-5-expressing CHO-K1 cells. (A) CHO-K1
cells were transiently transfected with a nectin-1, HVEM, or 3-OST-5
plasmid. gD receptor-expressing cells, along with naturally susceptible
Vero cells and cultured CF, were plated and treated with heparinases
II and III (4 U/ml) or PBS buffer for 2 h and infected with HSV-
1(KOS) gL86 at 35 PFU/cell for 2 h. During the 2-h infection, cells
were either spun at 37°C or kept in an incubator. Infection was then
continued for an additional 4 h, the plates were rinsed, and viral entry
was measured by determining OD410. Results from heparinase-un-
treated and unspun cells (considered positive controls) are shown as
black bars, while those from heparinase-treated and unspun or spun
cells are shown as white and gray bars, respectively. Data represent the
mean  the standard deviation of results in triplicate wells in a rep-
resentative experiment. The experiment was repeated three times with
similar results. (B) Spinoculation of heparinase-treated CF recovers
entry of CMV but not HSV-1. Cultured CF plated in a 96-well plate
were treated with heparinases II and III (4 U/ml) or PBS buffer for 3 h
and infected with reporter viruses HSV-1(KOS) gL86 and CMV at 35
PFU/cell for 2 h. During the 2-h infection, cells were spun at 37°C or
kept in an incubator unspun. Infection was then continued for an
additional 4 h, and viral entry was measured by determining OD410.
Results from heparinase-untreated and unspun cells (considered pos-
itive controls) are shown as black bars, while those from heparinase-
treated unspun or spun cells are shown as white and gray bars, respec-
tively. Data represent the mean  the standard deviation of results in
triplicate wells in a representative experiment. The experiment was
repeated three times with similar results.
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blocking fusion but also implicate 3-OS HS as the major me-
diator of membrane fusion for CF.
DISCUSSION
Although 3-OS-HS is known to be a receptor for HSV-1 gD
(41, 57, 61, 63, 68, 69), its role in the infection of a human
target cell type has remained unclear. It is well documented
that during infection of its natural host, HSV-1 encounters
different types of cells. Viral entry into these cells is critical for
the survival of the virions and for viral spread from the initial
sites of infection to neurons and cells of the immune system.
The viral receptors on these cells could determine which cells
are productively infected, which cells establish latent infec-
tions, and the nature of the immune response. Therefore, to
study the pathogenesis of HSV-1 infections, it is crucial to
identify the viral receptors that function on various target cells.
Despite the fact that HSK is a blinding disease, the cellular
receptors for HSV-1 entry into the cells of the stroma remain
unknown. We cultured human CF from a 47-year-old donor’s
eye to develop an in vitro model for studies of HSV-1 entry and
replication and for identification of cellular mediators of entry.
Quite unexpectedly, we did not detect expression of a well-
studied HSV-1 entry receptor, nectin-1, in CF or in the stroma
of the murine cornea (64). Thus, it seemed logical that entry
into CF was likely mediated by the other two entry receptors,
namely, HVEM and/or 3-OS HS. Since anti-HVEM entry-
blocking antibodies (40) failed to significantly block entry into
CF, our focus switched to 3-OS HS as the potential entry
receptor. Adding further strength to this possibility, heparinase
enzymes almost completely abolished HSV-1 entry into cul-
tured CF (Fig. 4A), gD binding exhibited sensitivity to enzyme
treatment (Fig. 4B and C), and the entry-blocking effect of an
anti-HS antibody (10E4) was more pronounced on CF com-
pared to HeLa cells (data not shown).
Since HS can help with attachment and fusion, to verify that
the fusion step was indeed affected by HS removal, a spinocu-
lation assays was used (51). It was clear that, similar to HSV-1
entry into 3-OST-5-expressing CHO-K1 cells, HSV-1 entry
into heparinase-treated CF could not be restored by spinocu-
lation (Fig. 5), implying that HS removal from CF was affecting
fusion as well. By contrast, Vero and CHO-K1 cells expressing
HVEM or nectin-1 still showed marked enhancement of entry
during spinoculation after the cell surface HS was removed.
The centrifugal force of spinoculation is known to enhance
virus attachment in the absence of HS and apparently can fully
or partially restore entry into HVEM- or nectin-1-expressing
cells (51). The lack of recovery by spinoculation in CF suggests
that, unlike HVEM-expressing CHO-K1 cells, HVEM is not a
major receptor in cultured CF. Expression of 3-OS HS on CF
was also demonstrated by disaccharide analysis, and its gD-
binding ability was verified (see Results). This further strength-
ens the notion that 3-OS HS could act as a major mediator of
HSV-1 entry into CF. Collectively, the present study, the first
of its kind, demonstrates a significant role for a modified form
of HS (3-OS HS) as an entry receptor in CF, a cell type that is
naturally susceptible to HSV-1 entry.
The knowledge that 3-OS HS is the receptor for entry into
CF is useful for many reasons. It is expected to pave the way
for the development of anti-3-OS HS compounds and antibod-
ies that can potentially block infection of CF in vitro with
cultured cells and ultimately in vivo with an animal model(s). It
is also likely to provide new information related to the patho-
genesis of HSK. It is still unknown why, despite recurrent
episodes of epithelial keratitis, many individuals do not de-
velop HSK, and the virus is rarely detected in the stroma. One
possibility relates to the availability of receptors on the cell
surface. Since expression of 3-OS HS in vivo is very tightly
regulated (16, 17), its availability on the cells of the stroma
could be a limiting factor resulting in relatively rare occurrence
of infection of the stroma. Conceivably, trauma to the cells of
the stroma, in certain cases, could induce the expression of
3-OS HS, which in turn could lead to HSV-1 entry and infec-
tion of the stroma. It appears that differential expression of
various HSV-1 receptors may indeed influence the course of
HSV-1 infection in human cell types. For instance, HVEM is
expressed in lymphoid cells, trabecular meshwork cells, and
fibroblasts but only weakly in human brain tissues (37, 40, 62).
On the other hand, nectin-1 is highly expressed in central
nervous system, corneal epithelium and endothelium, and
neuronal cell lines (8, 32, 64). Therefore, it is suggested that
nectin-1 probably plays an important role during HSV-1 entry
and spread in neuronal cells and associated latency while
HVEM is important for HSV-1 invasion of the cells of lym-
phoid and trabecular tissues (37, 40, 66). By analogy, it is also
likely that 3-OS HS can facilitate the entry of virions into the
stroma and thereby allow the virus or the host’s immune sys-
tem to initiate HSK. In any case, more in vivo data are needed
to establish the significance of 3-OS HS during infection of the
stroma.
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